세계의 고칼슘혈증 치료 시장 보고서(2025년)

Hypercalcemia Treatment Global Market Report 2025

US $ 4,490 ￦ 6,181,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,934,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,688,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

고칼슘혈증 치료제 시장 규모는 향후 몇 년 동안 급성장할 것으로 예상됩니다. 예측 기간 동안의 성장은 만성 신장 질환의 유병률 증가, 고혈압 환자 수 증가, 신약 개발에 대한 투자 증가, 인식 제고 및 환자 역량 강화, 정부 노력에 기인할 수 있습니다. 예측 기간의 주요 트렌드에는 향상된 진단 도구 및 기술, 치료 옵션의 발전, 혁신적인 약물 개발, 의료 서비스 제공자 간의 협력 증가 등이 포함됩니다.

부갑상선 질환의 유병률 증가는 고칼슘혈증 치료 시장의 확장을 주도할 것으로 예상됩니다. 부갑상선 장애는 부갑상선 호르몬(PTH)의 생산을 통해 체내 칼슘 수치를 조절하는 부갑상선에 영향을 미칩니다. 인구 고령화, 인식 증가, 진단 능력 향상, 원발성 부갑상선 기능 항진증 및 만성 신장 질환과 같은 질환의 발병률 증가 등 여러 요인이 이러한 질환의 유병률 증가에 기여하고 있습니다. 고칼슘혈증 치료는 칼슘 수치 상승을 조절하고 신장 결석 및 골 손실과 같은 합병증을 예방하며 전반적인 대사 균형을 유지함으로써 부갑상선 질환을 관리하는 데 중요한 역할을 합니다. 예를 들어, 미국 정부 기관인 국립보건원(NIH)에 따르면 미국의 부갑상선 기능 저하증은 10만 명당 6.4-37명이 앓고 있는 것으로 추정되며, 그 중 75%가 갑상선 절제술이나 두경부 수술의 합병증으로 인해 발생하는 것으로 나타났습니다. 따라서 부갑상선 질환의 유병률 증가는 고칼슘혈증 치료 시장의 성장을 촉진하고 있습니다.

고칼슘혈증 치료 시장의 선도 기업들은 칼슘과 인 조절을 강화하고 치료 결과를 개선하기 위해 인산염 결합제와 같은 혁신적인 솔루션을 개발하는 데 주력하고 있습니다. 인산염 결합제는 소화관에서 인산염 흡수를 방지하는 약물로, 신장 질환이나 고칼슘혈증 환자의 높은 인산염 수치를 관리하는 데 일반적으로 사용됩니다. 예를 들어, 2024년 5월 인도에 본사를 둔 제약 회사인 스트라이드 파마 사이언스 리미티드는 미국 식품의약국(FDA)으로부터 세벨라머 탄산염 정제 800mg에 대한 승인을 받았습니다. 이 정제는 식이 인산염과 결합하여 흡수를 방지함으로써 만성 신장 질환 환자의 고인산혈증을 효과적으로 관리하여 뼈 건강을 유지하고 인산염 수치 상승과 관련된 심혈관 위험을 줄이는 데 도움을 줍니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 고칼슘혈증 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 고칼슘혈증 치료 시장 : 성장률 분석
• 세계의 고칼슘혈증 치료 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 고칼슘혈증 치료 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 고칼슘혈증 치료 총 시장 규모(TAM)

제6장 시장 세분화

• 세계의 고칼슘혈증 치료 시장 : 약물 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 비스포스포네이트
• 칼시토닌
• 글루코 코르티코이드
• 데노스맙
• 칼슘 자극제
• 기타 약물의 유형
• 세계의 고칼슘혈증 치료 시장 : 적응증별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 원발성 갑상선 기능 항진증
• 악성종양에 의한 고칼슘혈증
• 기타 적응증
• 세계의 고칼슘혈증 치료 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원 약국
• 소매 약국
• 온라인 약국
• 세계의 고칼슘혈증 치료 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 클리닉
• 세계의 고칼슘혈증 치료 시장 : 비스포스포네이트 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 졸레드론산
• 파미드론산
• 알렌드로네이트
• 세계의 고칼슘혈증 치료 시장 : 칼시토닌 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 연어 칼시토닌
• 합성 칼시토닌
• 세계의 고칼슘혈증 치료 시장 : 글루코 코르티코이드 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 프레드니손
• 덱사메타손
• 하이드로코르티손
• 세계의 고칼슘혈증 치료 시장 : 데노스맙 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 데노스맙 단일 치료
• 데노스맙 병용 치료
• 세계의 고칼슘혈증 치료 시장 : 칼슘 자극제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 시나칼세토
• 에테르칼세티드
• 세계의 고칼슘혈증 치료 시장 : 기타 약물 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 질산갈륨
• 미트라마이신

제7장 지역별 및 국가별 분석

• 세계의 고칼슘혈증 치료 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 고칼슘혈증 치료 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 고칼슘혈증 치료 시장 : 경쟁 구도
• 고칼슘혈증 치료 시장 : 기업 프로파일
  • Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Roche Holding AG 개요, 제품 및 서비스, 전략 및 재무 분석
  • AbbVie Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • AstraZeneca plc 개요, 제품 및 서비스, 전략 및 재무 분석
  • Novartis AG 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• GSK plc
• Eli Lilly and Company
• Amgen Inc.
• Merck KGaA
• Fresenius Medical Care AG & Co. KGaA
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Ipsen SA
• Kyowa Kirin Co. Ltd.
• Hikma Pharmaceuticals plc
• Endo International plc
• OPKO Health Inc.
• Ferring Pharmaceuticals A/S
• Rockwell Medical Inc.
• Strides Pharma Science Limited

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 고칼슘혈증 치료 시장(2029년) : 새로운 기회를 제공하는 국가
• 고칼슘혈증 치료 시장(2029년) : 새로운 기회를 제공하는 부문
• 고칼슘혈증 치료 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

HBR

영문 목차

영문목차

Hypercalcemia treatment involves the medical management of elevated calcium levels in the blood caused by conditions such as hyperparathyroidism or malignancies. Treatment options include hydration, diuretics, bisphosphonates, and calcitonin to lower calcium levels and prevent complications. It is utilized in both emergency and long-term care settings to prevent kidney damage, neurological issues, and cardiac dysfunction.

The primary drug types for hypercalcemia treatment include bisphosphonates, calcitonin, glucocorticoids, denosumab, calcimimetics, and others. Bisphosphonates are a class of medications that treat bone diseases by inhibiting osteoclast activity, reducing bone breakdown. The treatment is indicated for conditions such as primary hyperparathyroidism, hypercalcemia of malignancy, and others. These medications are distributed through various channels, including hospitals, retail pharmacies, and online pharmacies, and are used by multiple end-users, such as hospitals and clinics.

The hypercalcemia treatment market research report is one of a series of new reports from The Business Research Company that provides hypercalcemia treatment market statistics, including the hypercalcemia treatment industry global market size, regional shares, competitors with the hypercalcemia treatment market share, detailed hypercalcemia treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the hypercalcemia treatment industry. This hypercalcemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hypercalcemia treatment market size has grown rapidly in recent years. It will grow from $16.44 billion in 2024 to $18.34 billion in 2025 at a compound annual growth rate (CAGR) of 11.5%. The growth during the historic period can be attributed to increasing awareness of hypercalcemia, a growing geriatric population, a rise in cancer cases, greater disease awareness, and the increasing prevalence of parathyroid disorders.

The hypercalcemia treatment market size is expected to see rapid growth in the next few years. It will grow to $28.31 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth during the forecast period can be attributed to the rising prevalence of chronic renal disease, the increasing number of patients with hypertension, higher investment in developing novel medications, greater awareness and patient empowerment, and government initiatives. Key trends in the forecast period include enhanced diagnostic tools and techniques, advancements in treatment options, the development of innovative drugs, and increased collaborations among healthcare providers.

The increasing prevalence of parathyroid disorders is expected to drive the expansion of the hypercalcemia treatment market. Parathyroid disorders affect the parathyroid glands, which regulate calcium levels in the body through the production of parathyroid hormone (PTH). Several factors contribute to the rising prevalence of these disorders, including an aging population, increased awareness, improved diagnostic capabilities, and a growing incidence of conditions such as primary hyperparathyroidism and chronic kidney disease. Hypercalcemia treatment plays a crucial role in managing parathyroid disorders by controlling elevated calcium levels, preventing complications such as kidney stones and bone loss, and maintaining overall metabolic balance. For example, according to the National Institute of Health (NIH), a US-based government agency, hypoparathyroidism in the United States is estimated to affect 6.4 to 37 per 100,000 person-years, with 75% of cases resulting from complications of thyroidectomy or head and neck surgery. As a result, the increasing prevalence of parathyroid disorders is fueling the growth of the hypercalcemia treatment market.

Leading companies in the hypercalcemia treatment market are focusing on developing innovative solutions, such as phosphate binders, to enhance calcium and phosphorus regulation and improve treatment outcomes. Phosphate binders are medications that prevent phosphate absorption in the digestive tract and are commonly used to manage high phosphate levels in patients with kidney disease or hypercalcemia. For instance, in May 2024, Strides Pharma Science Limited, an India-based pharmaceutical company, received approval from the United States Food and Drug Administration (FDA) for its Sevelamer Carbonate Tablets, 800 mg. These tablets effectively manage hyperphosphatemia in patients with chronic kidney disease by binding dietary phosphate and preventing its absorption, helping to maintain bone health and reduce cardiovascular risks associated with elevated phosphate levels.

In December 2024, Teijin Pharma Limited, a Japan-based pharmaceutical company, partnered with Ascendis Pharma A/S to introduce innovative prodrug technology for hypoparathyroidism treatment. This collaboration enables Teijin to utilize advanced prodrug technology that provides sustained PTH levels, potentially offering a more effective and convenient treatment option compared to existing therapies. Ascendis Pharma A/S, a Denmark-based company, specializes in developing innovative prodrugs for treating hypoparathyroidism in adults.

Major players in the hypercalcemia treatment market are Pfizer Inc., Roche Holding AG, AbbVie Inc., AstraZeneca plc, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Merck KGaA, Fresenius Medical Care AG & Co. KGaA, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Ipsen SA, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, OPKO Health Inc., Ferring Pharmaceuticals A/S, Rockwell Medical Inc., Strides Pharma Science Limited.

North America was the largest region in the hypercalcemia treatment market in 2024. The regions covered in hypercalcemia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hypercalcemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hypercalcemia treatment market consists of revenues earned by entities through services such as surgical treatment, dietary modifications, and bisphosphonates. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypercalcemia treatment market also includes sales of metabolic testing devices, body composition analyzers, and wearable fitness trackers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hypercalcemia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hypercalcemia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hypercalcemia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hypercalcemia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Bisphosphonates; Calcitonin; Glucocorticoids; Denosumab; Calcimimetics; Other Drug Types
• 2) By Indication: Primary Hyperthyroidism; Hypercalcemia Of Malignancy; Other Indications
• 3) By Distribution Channel: Hospitals Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By End-Users: Hospitals; Clinics
• Subsegments:
• 1) By Bisphosphonates: Zoledronic Acid; Pamidronate; Alendronate
• 2) By Calcitonin: Salmon Calcitonin; Synthetic Calcitonin
• 3) By Glucocorticoids: Prednisone; Dexamethasone; Hydrocortisone
• 4) By Denosumab: Denosumab (Monotherapy); Denosumab Combination Therapy
• 5) By Calcimimetics: Cinacalcet; Etelcalcetide
• 6) By Other Drug Types: Gallium Nitrate; Mithramycin
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; AbbVie Inc.; AstraZeneca plc; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hypercalcemia Treatment Market Characteristics

3. Hypercalcemia Treatment Market Trends And Strategies

4. Hypercalcemia Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Hypercalcemia Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hypercalcemia Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hypercalcemia Treatment Market Growth Rate Analysis
• 5.4. Global Hypercalcemia Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hypercalcemia Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hypercalcemia Treatment Total Addressable Market (TAM)

6. Hypercalcemia Treatment Market Segmentation

• 6.1. Global Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bisphosphonates
• Calcitonin
• Glucocorticoids
• Denosumab
• Calcimimetics
• Other Drug Types
• 6.2. Global Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Hyperthyroidism
• Hypercalcemia of Malignancy
• Other Indications
• 6.3. Global Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Hypercalcemia Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• 6.5. Global Hypercalcemia Treatment Market, Sub-Segmentation Of Bisphosphonates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Zoledronic Acid
• Pamidronate
• Alendronate
• 6.6. Global Hypercalcemia Treatment Market, Sub-Segmentation Of Calcitonin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Salmon Calcitonin
• Synthetic Calcitonin
• 6.7. Global Hypercalcemia Treatment Market, Sub-Segmentation Of Glucocorticoids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisone
• Dexamethasone
• Hydrocortisone
• 6.8. Global Hypercalcemia Treatment Market, Sub-Segmentation Of Denosumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Denosumab (Monotherapy)
• Denosumab Combination Therapy
• 6.9. Global Hypercalcemia Treatment Market, Sub-Segmentation Of Calcimimetics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cinacalcet
• Etelcalcetide
• 6.10. Global Hypercalcemia Treatment Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gallium Nitrate
• Mithramycin

7. Hypercalcemia Treatment Market Regional And Country Analysis

• 7.1. Global Hypercalcemia Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hypercalcemia Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hypercalcemia Treatment Market

• 8.1. Asia-Pacific Hypercalcemia Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hypercalcemia Treatment Market

• 9.1. China Hypercalcemia Treatment Market Overview
• 9.2. China Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hypercalcemia Treatment Market

• 10.1. India Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hypercalcemia Treatment Market

• 11.1. Japan Hypercalcemia Treatment Market Overview
• 11.2. Japan Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hypercalcemia Treatment Market

• 12.1. Australia Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hypercalcemia Treatment Market

• 13.1. Indonesia Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hypercalcemia Treatment Market

• 14.1. South Korea Hypercalcemia Treatment Market Overview
• 14.2. South Korea Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hypercalcemia Treatment Market

• 15.1. Western Europe Hypercalcemia Treatment Market Overview
• 15.2. Western Europe Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hypercalcemia Treatment Market

• 16.1. UK Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hypercalcemia Treatment Market

• 17.1. Germany Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hypercalcemia Treatment Market

• 18.1. France Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hypercalcemia Treatment Market

• 19.1. Italy Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hypercalcemia Treatment Market

• 20.1. Spain Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hypercalcemia Treatment Market

• 21.1. Eastern Europe Hypercalcemia Treatment Market Overview
• 21.2. Eastern Europe Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hypercalcemia Treatment Market

• 22.1. Russia Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hypercalcemia Treatment Market

• 23.1. North America Hypercalcemia Treatment Market Overview
• 23.2. North America Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hypercalcemia Treatment Market

• 24.1. USA Hypercalcemia Treatment Market Overview
• 24.2. USA Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hypercalcemia Treatment Market

• 25.1. Canada Hypercalcemia Treatment Market Overview
• 25.2. Canada Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hypercalcemia Treatment Market

• 26.1. South America Hypercalcemia Treatment Market Overview
• 26.2. South America Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hypercalcemia Treatment Market

• 27.1. Brazil Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hypercalcemia Treatment Market

• 28.1. Middle East Hypercalcemia Treatment Market Overview
• 28.2. Middle East Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hypercalcemia Treatment Market

• 29.1. Africa Hypercalcemia Treatment Market Overview
• 29.2. Africa Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hypercalcemia Treatment Market Competitive Landscape And Company Profiles

• 30.1. Hypercalcemia Treatment Market Competitive Landscape
• 30.2. Hypercalcemia Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Hypercalcemia Treatment Market Other Major And Innovative Companies

• 31.1. GSK plc
• 31.2. Eli Lilly and Company
• 31.3. Amgen Inc.
• 31.4. Merck KGaA
• 31.5. Fresenius Medical Care AG & Co. KGaA
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Sandoz International GmbH
• 31.8. Ipsen SA
• 31.9. Kyowa Kirin Co. Ltd.
• 31.10. Hikma Pharmaceuticals plc
• 31.11. Endo International plc
• 31.12. OPKO Health Inc.
• 31.13. Ferring Pharmaceuticals A/S
• 31.14. Rockwell Medical Inc.
• 31.15. Strides Pharma Science Limited

32. Global Hypercalcemia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hypercalcemia Treatment Market

34. Recent Developments In The Hypercalcemia Treatment Market

35. Hypercalcemia Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Hypercalcemia Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hypercalcemia Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hypercalcemia Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료